Literature DB >> 17021824

Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters.

Wen-Chiuan Tsai1, Lai-Fa Sheu, Shin Nieh, Cheng-Ping Yu, Gung-Huan Sun, Yeh-Feng Lin, Ann Chen, Jong-Shiaw Jin.   

Abstract

EMMPRIN and fascin are important factors in tumor invasion and progression. We tested the hypothesis that expression of EMMPRIN and fascin correlate with clinicopathological parameters of renal cell carcinoma (RCC). Immunohistochemical analysis of EMMPRIN and fascin were performed in tissue microarrays of 100 surgical specimens, including 35 clear-cell RCC (CRCC), 21 clear-cell RCC with granular differentiation (GRCC), 12 chromophobe RCC (ChRCC), 8 papillary RCC (PRCC), 9 carcinoma of the collecting duct of Bellini (CDC), 10 clear-cell RCC with sarcomatoid differentiation (SRCC), and 6 metastatic RCC. Average immunoscores of EMMPRIN were 100.8 in CRCC, 195.2 in GRCC, 298.4 in ChRCC, 219.2 in PRCC, 186.1 in CDC, 226.9 in SRCC, and 151.7 in metastatic RCC. Among all included cases, average EMMPRIN immunoscores were 84.6 in grade I, 130.4 in grade II, 184.3 in grade III, and 223.5 in grade IV. Additionally, average immunostaining scores of fascin were 53.6 in CRCC, 289.3 in GRCC, 193.3 in ChRCC, 151.8 in PRCC, 181.3 in CDC, 275.4 in SRCC, and 131.7 in metastatic RCC. Average fascin immunoscores were 59.3 in grade I, 91.6 in grade II, 130.2 in grade III, and 194.7 in grade IV. Higher EMMPRIN and fascin immunoscores also correlated significantly with TNM stages and survival rates in RCC. Significant correlation was found between EMMPRIN and fascin expression. In conclusion, higher expression of EMMPRIN and fascin correlate significantly with histological grades, clinical stages, and survival rates of RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021824     DOI: 10.1007/s00345-006-0110-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

Review 1.  Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression.

Authors:  Kazuki Nabeshima; Hiroshi Iwasaki; Kaori Koga; Hironobu Hojo; Junji Suzumiya; Masahiro Kikuchi
Journal:  Pathol Int       Date:  2006-07       Impact factor: 2.534

2.  Fascin expression in 90 patients with glioblastoma multiforme.

Authors:  Andres A Roma; Richard A Prayson
Journal:  Ann Diagn Pathol       Date:  2005-12       Impact factor: 2.090

3.  Current prognostic factors--renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).

Authors:  J R Srigley; R V Hutter; A B Gelb; D E Henson; G Kenney; B F King; S Raziuddin; T M Pisansky
Journal:  Cancer       Date:  1997-09-01       Impact factor: 6.860

Review 4.  Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?

Authors:  Yosuke Hashimoto; Marek Skacel; Josephine C Adams
Journal:  Int J Biochem Cell Biol       Date:  2005-09       Impact factor: 5.085

5.  The prognostic relevance of fascin expression in human gastric carcinoma.

Authors:  Yosuke Hashimoto; Yutaka Shimada; Junichiro Kawamura; Seiji Yamasaki; Masayuki Imamura
Journal:  Oncology       Date:  2004       Impact factor: 2.935

6.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas.

Authors:  A Okada; J P Bellocq; N Rouyer; M P Chenard; M C Rio; P Chambon; P Basset
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells.

Authors:  Jin-Ming Yang; Zude Xu; Hao Wu; Hongguang Zhu; Xiaohua Wu; William N Hait
Journal:  Mol Cancer Res       Date:  2003-04       Impact factor: 5.852

8.  Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays.

Authors:  Sharon L Swierczynski; Anirban Maitra; Susan C Abraham; Christine A Iacobuzio-Donahue; Raheela Ashfaq; John L Cameron; Richard D Schulick; Charles J Yeo; Ayman Rahman; David A Hinkle; Ralph H Hruban; Pedram Argani
Journal:  Hum Pathol       Date:  2004-03       Impact factor: 3.466

9.  cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein.

Authors:  F M Duh; F Latif; Y Weng; L Geil; W Modi; T Stackhouse; F Matsumura; D R Duan; W M Linehan; M I Lerman
Journal:  DNA Cell Biol       Date:  1994-08       Impact factor: 3.311

10.  Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer.

Authors:  A Grothey; R Hashizume; A A Sahin; P D McCrea
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

View more
  13 in total

1.  Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas.

Authors:  Xue-Cheng Bi; Jiu-Min Liu; Hui-Chang He; Yong-Kang Ye; Zhao-Dong Han; Qi-Shan Dai; Yu-Xiang Liang; Chao Cai; Jia-Hong Chen; Xi-Bin Chen; Guo-Qiang Qin; Guo-Hua Zeng; Wei-De Zhong
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

2.  Fascin over expression is associated with dysplastic changes in sinonasal inverted papillomas: a study of 47 cases.

Authors:  Hope H Wu; Samiah Zafar; Youming Huan; Herman Yee; Luis Chiriboga; Beverly Y Wang
Journal:  Head Neck Pathol       Date:  2009-08-14

3.  Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry.

Authors:  Wei Wu; Rongbing Wang; Hui Liu; Jie Peng; Damao Huang; Bo Li; Jingde Ruan
Journal:  Med Oncol       Date:  2008-07-30       Impact factor: 3.064

4.  Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics.

Authors:  Dalia Mohamed Abd El-Rehim; Nehad Mohamed Reda Abd El-Maqsoud; Amr Mohamed Abd El-Hamid; Tarek Khalaf Fath El-Bab; Ehab Mohamed Galal
Journal:  Mol Clin Oncol       Date:  2013-01-02

Review 5.  The roles of CD147 and/or cyclophilin A in kidney diseases.

Authors:  Xin Qu; Chunting Wang; Jicheng Zhang; Guoqiang Qie; Jianxin Zhou
Journal:  Mediators Inflamm       Date:  2014-12-17       Impact factor: 4.711

Review 6.  CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.

Authors:  Xiaoyan Xin; Xianqin Zeng; Huajian Gu; Min Li; Huaming Tan; Zhishan Jin; Teng Hua; Rui Shi; Hongbo Wang
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

7.  The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies.

Authors:  Hengwei Fan; Wanwan Yi; Chenxing Wang; Jisheng Wang
Journal:  Oncotarget       Date:  2017-07-31

8.  EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas.

Authors:  Wen-Chiuan Tsai; Ying Chen; Li-Chun Huang; Herng-Sheng Lee; Hsin-I Ma; Shih-Ming Huang; Huey-Kang Sytwu; Dueng-Yuan Hueng
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

9.  Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis.

Authors:  Anja Rabien; Carsten Stephan; Ergin Kilic; Wilko Weichert; Glen Kristiansen; Kurt Miller; Klaus Jung; Andreas Erbersdobler
Journal:  J Transl Med       Date:  2013-10-16       Impact factor: 5.531

10.  Expression and clinical significance of CD147 in renal cell carcinoma: a meta-analysis.

Authors:  Hui Li; Dongwen Wu; Shupeng Shi; Yadong Xu; Ling Wei; Jing Liu; Yanting Liu
Journal:  Oncotarget       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.